SURVYR

HUM

Humana Inc.
$414.85
−$2.37 (0.57%)Oct 27 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-44%-18%+7%+32%+58%Oct 2025Oct 2026Apr 202652w high $456.5052w low $163.11
HUMSPY
Wall St. Highest PT $596.00 (+43.7%) Wall St. Avg PT $465.12 (+12.1%)
$162$275$388$501$614POC $385Hi $596Avg $465
Underwater Drawdown %Max DD -44.3%Current -4.3%
0.0%-44.3%
Relative Strength vs SPY+29.9% vs SPYOutperforming
+48%0%-48%
1W
−$12.53 (2.93%)
1M
+$16.92 (4.25%)
3M
+$26.14 (6.72%)
6M
+$185.67 (81.02%)
YTD
+$160.61 (63.18%)
1Y
+$125.66 (43.45%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
26 analysts · mean score 1.96
1 = Strong Buy · 5 = Sell
Strong Buy312%
Buy1350%
Hold935%
Underperform14%
Sell00%
Wall Street consensus
Analyst price targets
Current price$414.85
Average target$465.12
+$50.27 (+12.1%) upsideaverage target vs current price
CurrentAverageMedian
Low$280.00
Median$473.00
High$596.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-13 · Mizuho reiterated Outperform on HUM
Reiterated
2026-10-12 · UBS reiterated Neutral on HUM
Reiterated
2026-10-12 · Truist Securities reiterated Hold on HUM
Reiterated
2026-10-12 · Oppenheimer reiterated Outperform on HUM
Upgrade
2026-10-12 · Raymond James upgraded HUM from Market Perform to Outperform
Reiterated
2026-10-09 · Barclays reiterated Overweight on HUM
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$49.8B
P/E (last 12 months)39.7
P/E (next 12 months, estimated)24.3
52-week range$163.11 – $456.50
Revenue growth (latest quarter vs a year ago)+26.2%
Dividend yield0.85%
Analyst consensusBuy (24)
Average analyst price target$465.12 (+12%)

What they do

Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management.

Healthcare · Healthcare Plans
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
72nd percentile in sector
B+
12-1 return: +38.7%
Percentile within its GICS sector across the S&P 1500.
Growth
86th percentile in sector
A-
Revenue growth (YoY): +26.2%
Percentile within its GICS sector across the S&P 1500.
Value
51st percentile in sector
C+
Forward E/P: 4.1% · EBITDA/EV: 8.9%
Percentile within its GICS sector across the S&P 1500.
Profitability
32nd percentile in sector
C-
Profit margin: +0.9% · Return on equity: +6.9%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 65 of 499 · 12-month momentum 48.9%
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

HUM earningsNext report in 9 days
Next report · quarter Sep 2026
Fri Nov 6, 2026Before the open
EPS consensus-$1.00 range -$1.16–-$0.60
Revenue consensus$40.9B 17 analysts
Last 4 quarters · EPS vs estimate
Jul 29, 2026$7.61est $7.00+8.8%Above estimates
Apr 29, 2026$10.31est $10.20+1.1%Above estimates
Feb 11, 2026-$3.96est -$3.99+0.7%In line with estimates
Nov 5, 2025$3.24est $2.83+14.6%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-27 18:23:27 ET
24-1025-0225-0425-0725-1126-0226-0426-07-3.9911.58
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$40.9B+26.2%
2026-03-31$39.6B–
2025-12-31$32.5B–
2025-09-30$32.6B–
2025-06-30$32.4B–

Recent dividends

2026-06-26: $0.885 · 2026-03-27: $0.885 · 2025-12-26: $0.885 · 2025-09-26: $0.885 · 2025-06-27: $0.885 · 2025-03-28: $0.885 · 2024-12-31: $0.885 · 2024-09-30: $0.885

News & catalysts

More news
Centene to Report Q3 Earnings: Buy, Sell or Hold the Stock?
Zacks · Oct 22
Rating changes
Reiterated
2026-10-13 · Mizuho reiterated Outperform on HUM
Reiterated
2026-10-12 · UBS reiterated Neutral on HUM
Reiterated
2026-10-12 · Truist Securities reiterated Hold on HUM
Reiterated
2026-10-12 · Oppenheimer reiterated Outperform on HUM
Upgrade
2026-10-12 · Raymond James upgraded HUM from Market Perform to Outperform
Reiterated
2026-10-09 · Barclays reiterated Overweight on HUM

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-27 18:23:27 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026